Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
Rheumatology
•
Rheumatoid Arthritis
•
General Rheumatology
•
Inflammatory arthritis
•
Orthopedics
What is your approach to assessing inflammatory arthritis flares in joints that have been replaced (such as knees)?
Related Questions
What is your approach to methotrexate use (or avoidance) in patients with varying MTHFR mutations?
What is your approach to differentiating RA-ILD from medication toxicity (I.e. from methotrexate)?
In a patient with a history of seropositive erosive RA who has undergone treatment for a periprosthetic joint infection and currently has an antibiotic spacer in place with clinical improvement, what is the appropriate timing and strategy for restarting DMARDs and/or biologic therapy to balance infection risk with RA disease control?
How do you approach use of DMARDs and/or biologics for inflammatory arthritis in patients with a history of seizure disorder on anti-epileptic medications?
How do you manage transaminitis in a patient receiving TNF alpha inhibitors?
For patients who do not have access to biologic therapies, what are some csDMARD combination pearls or tips that you have that have particular efficacy in different rheumatologic diseases?
Are you comfortable trying a different JAK inhibitor in patients with prior JAK inhibitor allergy?
How do you manage pleuroparenchymal fibroelastosis in a patient with seronegative RA that is progressing on Rituxan and DMARD therapy?
What is your approach to differentiating tender spots (as in fibromyalgia) and enthesitis (as in axSpA)?
What is the interpretation of an IGRA with positive TB wells and negative nil and negative mitogen wells?
